AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-119657850/pfizer-generics-news-brief.html" title="Facts and information about Pfizer.(Generics News)(Brief Article)">Pfizer.(Generics News)(Brief Article)</a>

Close Set up an RSS feed that alerts you when new articles from Drug Store News are available.

Frequently asked questions about RSS feeds

Pfizer.(Generics News)(Brief Article)

Drug Store News

| July 19, 2004 | Frederick, James | COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

In a June 29 decision, Judge Dickinson Debevoise of the U.S. District Court for the District of New Jersey upheld the patent protecting Pfizer's blood pressure medicine Accupril (quinapril hydrochloride) against Teva.

Consequently, the court issued an injunction blocking the approval of Teva's drug application until the February 2007 expiration of ...

Related articles from newspapers, magazines, journals, and more


Battle for generics.(News): Newspaper article from: Cape Times (South Africa) August 10, 2006 700+ words
FEW changes would do more to reduce healthcare costs quickly than making generic medications more widely available. Which is why bad news for Bristol-Myers Squibb could be good news for everyone else. Late last month, federal investigators raided the drug giant's New York offices looking for


Fast-lane for generics. (News in Brief).(drug patents)(Brief Article): Magazine article from: Chemistry and Industry November 4, 2002 700+ words
The US Senate has moved to reduce the time it takes to introduce generic competition against brand-name drugs. At present, pharmaceutical companies file lawsuits to protect their patents when challenged and are granted a 30-month stay in which rivals cannot enter the market. Wily pharma companies


Publix giving away select generics.(News)(Brief article): Magazine article from: Chain Drug Review September 3, 2007 700+ words
LAKELAND, Fla. -- Publix Super Markets Inc. has begun offering seven free generic oral antibiotics, many of them prescribed for children. The retailer is giving away supplies of up to 14 days of amoxicillin, cephalexin, sulfamethoxazole/trimethoprim (SMZ-TMP), ciprofloxacin (excluding ciprofloxacin


Actavis Group.(In other generics news)(terbinafine hydrochloride tablets)(Brief...: Magazine article from: Chain Drug Review August 20, 2007 700+ words
* Actavis Group. It has launched terbinafine hydrochloride tablets. Available in 250 mgs, the product is the generic equivalent to Novartis Pharmaceuticals Corp.'s Lamisil, a fungal treatment.


Alcorn Inc.(In other generics news)(Zaditor eye solution)(Brief article): Magazine article from: Chain Drug Review August 20, 2007 700+ words
* Alcorn Inc. It has received an FDA O.K. for a generic copy of Novartis' Zaditor eye solution. The product is known by its generic name of fumarate ophthalmic solution, 0.025%.


Barr Laboratories Inc.(In other generics news)(drug approval for...: Magazine article from: Chain Drug Review August 20, 2007 700+ words
* Barr Laboratories Inc. The company has been given regulatory approval for Dostinex (cabergoline) tablets, 0.5 mg. Barr's abbreviated new drug application was acquired from Teva Pharmaceuticals.


Wal-Mart ups ante on generics.(News)(generics program)(Wal-Mart Stores Inc. ): Magazine article from: Chain Drug Review Walden, Geoff October 22, 2007 700+ words
BENTONVILLE, Ark. -- Wal-Mart Stores Inc. has expanded its low-price generics program, adding birth control pills and medications for children. In its first year the program offered drugs for $4, many for conditions common among older people, including hypertension, diabetes and heart ailments. The


Lexapro gains ease fears of generics.(NEWS): Magazine article from: Medical Marketing & Media Iskowitz, Marc February 1, 2007 700+ words
LOSS OF PATENT protection on Pfizer's Zoloft last year caused analysts to raise warning flags about the whole class. But the surprisingly strong performance of Forest Labs' Lexapro brought reassuring news. Forest said last month that Lexapro earned $545.9 million for the three months ended Dec. 31,

For more facts and information, see all results